Head to Head Comparison: CannTrust (OTCMKTS:CNTTF) & Zymeworks (NASDAQ:ZYME)

Zymeworks (NASDAQ:ZYME) and CannTrust (OTCMKTS:CNTTF) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Valuation and Earnings

This table compares Zymeworks and CannTrust”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96 million	17.72	-$81.13 million	($1.37)	-18.77
CannTrust	$15.96 million	0.00	$7.39 million	$0.07	N/A

CannTrust has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than CannTrust, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Zymeworks has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, CannTrust has a beta of 4.52, indicating that its stock price is 352% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Zymeworks and CannTrust, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1	1	8	1	2.82
CannTrust	0	0	0	0	0.00

Zymeworks currently has a consensus price target of $37.00, indicating a potential upside of 43.86%. Given Zymeworks’ stronger consensus rating and higher probable upside, analysts plainly believe Zymeworks is more favorable than CannTrust.

Insider and Institutional Ownership

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 0.1% of CannTrust shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Zymeworks and CannTrust’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zymeworks	-126.92%	-37.97%	-25.31%
CannTrust	N/A	N/A	N/A

About Zymeworks

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

About CannTrust

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.